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Summary Activating mutations in glutamate dehydrogenase (GDH), de novo or
dominantly inherited, are responsible for the hyperinsulinism/hyperammonemia (HI/
HA) syndrome. Epilepsy has been frequently reported in association with mutations in
GDH, but the epilepsy phenotype has not been clearly determined. Here, we describe
a family with a dominantly inherited mutation in GDH. The mother, brother and both
sisters had myoclonic absence seizures, but only the mother and one sister had the
complete HI/HA pattern. For the two sisters with myoclonic absences, epilepsy
started during the second year of life while the brother, it started at 6 years. All 3
children showed the same EEG pattern characterized by photosensitive generalized
and irregular spike-wave discharges and runs of multiple spikes. The mother’s EEG
recordings were normal without photosensitivity. Magnetic resonance imaging (MRI)* Corresponding author at: Service de Neurologie Pe´diatrique et Maladies Me´taboliques, De´partement de Pe´diatrie, Hopital Necker
Enfants Malades, AP-HP, Paris V, Paris, France. Tel.: +33 1 42 16 26 99; fax: +33 1 44 49 48 50.
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and spectroscopy (MRS) were normal. A direct effect of the GDH mutation, perhaps in
combination with recurrent hypoglycemia and chronic hyperammonemia could pro-
vide a pathophysiological explanation for the epilepsy observed in this syndrome and
these are discussed.
# 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Activating mutations in glutamate dehydrogenase
(GDH) are de novomutations that produce a hetero-
geneous phenotype with (HI/HA) syndrome. Epi-
lepsy and mental retardation are frequentlyFigure 1 Index case (patient 1): (A) simultaneous video rec
associated with high amplitude generalized and irregular polys
with photic stimulation at frequencies at 10, 12 and 14 Hz
recording with EMG. Longitudinal bipolar montage. Amplitudassociated with mutations in GDH, but the epilepsy
phenotype has not been clearly determined and the
pathophysiological mechanisms are not yet under-
stood.1—4
HI/HA syndrome is characterized by hyperin-
sulinemic hypoglycemia and hyperammonemia.ording revealed a cluster of spontaneous myoclonic jerks
pikes and polyspike-waves. (B) Same EEG pattern observed
associated with massive myoclonic jerks. (Polygraphic
e decreased to 20 mV/mm.)
660 N. Bahi-Buisson et al.Hypoglycemia related to HI/HA syndrome is usually
less severe than hyperinsulinemic hypoglycemia
secondary to an ion channel disorder,5 with a good
response to medical treatment, namely diazoxide
and a protein restricted diet.1,6 Hyperammonemia,
up to 3—5 times normal, is asymptomatic1,2 and
resistant to treatment.
GDHmutations result in a gain of enzyme function
that leads to an increase of the oxidative deamina-
tion of glutamate to alpha-ketoglutarate and ammo-
nia. This increased enzymatic reaction is
responsible for increased Krebs cycle activity and
b-cell ATP/ADP ratio. The latter activates the KATP
channel with subsequent cell depolarization and
exaggerated insulin release.7
Recently, Razen et al. reported the association
of epilepsy with a gain of function mutation in
GDH in 14 patients.4 However, the clinical and
electrophysiological features of this epilepsy
were variable. Here, we describe a specific elec-
troclinical pattern of three affected children
from a family with dominantly transmitted GDH
mutation. In an attempt to explore further the
pathophysiological mechanisms underlying this
epilepsy, we will provide biochemical and imaging
data.Figure 2 Sister’s EEG pattern at 3 years (patient 3). Phot
rhythmic 2.5—3 spike-waves/s sometimes preceded by asym
Simultaneous video recording revealed loss of consciousness
atypical absence episodes lasted 5—8 s, sometimes associate
Amplitude decreased to 20 mV/mm.)Family report
The proband (patient 1) is a girl referred to us at 11
months of age for hypoglycemic seizures. She was
subsequently diagnosed with HI/HA syndrome, con-
firmed by the identification of a heterozygous acti-
vating GDH mutation in exon 6 in the GTP-binding
site (833 C > T, pArg221Cys).8,9 We then discovered
that her mother (patient 2), sister (patient 3) and
brother (patient 4) carried the same mutation in
GDH. One remaining brother was unaffected.
She was born at term and the pregnancy was
uneventful. She presented at the age of 11 months
with generalized tonic—clonic seizures associated
with hypoglycemia. On admission, neurological
examination was normal. Asymptomatic recurrent
hypoglycemia was diagnosed with the lowest
recorded glucose levels at 2 mmol/l. This was asso-
ciated with hyperammonemia (100—120 mmol/l)
with elevated glutamine levels (514 mmol/l, normal
range <50 mmol/l). Despite frequent feeds and
treatment with diazoxide, hypoglycemia persisted.
At the age of 13 months, she underwent a subtotal
pancreatectomy. After surgery, diazoxide was
stopped. However, hypoglycemia recurred after sur-
gery. This was well controlled by a protein restrictedic stimulation at 50 Hz frequency induced discharges of
metrical rhythmic activity in the right occipital area.
, staring and right upward elevation of the eyes. These
d with myoclonic jerks. (Longitudinal bipolar montage.
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at 80—100 mmol/l, did not fall with fasting or rise
with protein feeding and were independent of blood
glucose levels.
Interictal EEG recordings showed sleep-activated
photosensitive spike-wave paroxysms.
Myoclonic absences started at the age of 24
months. They were characterized by repeated
absence spells with eyelids myoclonia in association
with massive and bilateral myoclonia. Her level of
consciousness was impaired during the events but
recovered immediately after. The events occurred
more than 10 times per day. A 24 h EEG recording
with close monitoring of blood glucose and ammonia
levels, allowed us to record these episodes. They
occurred either in isolation or in clusters of 2—3 and
were associated with discharges of high amplitude
and irregular generalized spikes (Fig. 1A). They
occurred both spontaneously and with photic stimu-
lation (Fig. 1B).
Treatment with clobazam reduced the frequency
of myoclonic absences but did not abolish them.
Carbamazepine transitorily worsened the seizures
and was stopped. Levetiracetam in conjunction with
clobazam led to a 50% reduction in seizure fre-
quency.
Her mother (patient 2) presented with hypogly-
cemia during infancy, and this was well controlled byFigure 3 11-year-old brother’s EEG (patient 4). No spontane
20, 22 and 25 Hz frequency induced discharges of irregular an
absences. (Longitudinal bipolar montage.)frequent feeding. She also had generalized seizures
characterized by myoclonic absences with eyelid
myoclonia and sometimes leading to falls. Theses
seizures were controlled by sodium valproate until
the age of 9 years. At the age of 40 years, she was
seizure-free without medication. Glucose levels
were normal; however, her ammonia was
80 mmol/l. Her EEG was normal.
The proband’s sister (patient 3) seizure disorder
began at 3 years of age characterized by absence
seizures, with eyelid myoclonia and massive myo-
clonic jerks. Seizure frequency was between 3 and
10 per day. Sodium valproate and clobazam failed to
control her epilepsy, however, levetiracetam
allowed a partial reduction of her seizures. No
hypoglycemia was reported but her ammonia was
persistently recorded at 110—120 mmol/l. EEG
recordings displayed similarities with those of the
proband, with photosensitive discharges of irregular
and high amplitude spike-waves and polyspikes,
either asymptomatic or associated with myoclonic
absences (Fig. 2).
The elder brother (patient 4) presented with 3
episodes of myoclonic absences at the age of 6 years
without hypoglycemia, but mild hyperammonemia
was noted (90—110 mmol/l). No EEG was performed
before the age of 11 years. EEG recordings later
showed the same pattern of repeated and photo-ous abnormalities were observed but photic stimulation at
d high amplitude spike-waves associated with myoclonic
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Table 1 Biochemical results of patient 1
Laboratory parameter Patient 1 Controls
Mean NH3 level 125 mmol/l 15—40
Basal GDH activity 16.82 nmol/min/mg protein 17.86  1.8
Plasma glutamine 415 mmol/l 498  80
CSF glutamine 593 mmol/l 355—885
CSF catecholamines
 HVA 424 nmol/l 100—800 nmol/l
 5-HIAA 96 nmol/l 50—300 nmol/l
 3-OMD 57 nmol/l 0—50 nmol/l
CSF 4-amino butyric acid (GABA)
 Free GABA 0.157 mmol/l 0.032—0.167 mmol/l
 Total GABA 8.390 mmol/l 3.3—12.2 mmol/l
Abbreviations: NH3 (ammonium); CSF (cerebro-spinal fluid); HVA: (homovanillic acid); 5-HIAA (5-hydroxyindolacetic acid); 3-OMD (O-
methyl Dopa).sensitive discharges of spikes and polyspikes in
clusters, sometimes associated with massive myo-
clonia (Fig. 3).
In all the family, neuropsychological examination
revealed moderate to severe mental retardation
(respectively IQ 50 for patient 1, IQ 60 for patient
3, IQ 75 for patient 2 and 4).
MRI and MRS were performed all the 4 patients,
and were normal. Cerebro-spinal fluid (CSF) amino-
acid (glutamine) and CSF neurotransmitters (cate-
cholamine and GABA) studies were normal. Bio-
chemical results are summarized in Table 1.Discussion
Here, we report myoclonic absence epilepsy with
photosensitivity in three children of a family with a
dominantly inherited gain of function mutation in
GDH. The seizure pattern was similar in the three
children whereas the metabolic presentation varied
from a typical HI/HA syndrome in the index case to
isolated hyperammonemia in the sister and the
brother. The mother also presented hypoglycemia
followed by myoclonic absences during infancy and
hyperammonemia which persisted in adulthood. The
heterogeneity of the phenotype of HI/HA syndrome
has been reported,1,10 but the epilepsy, which seems
to be one of the main neurological symptom of the
disease, remains to be more clearly defined.
Indeed, in a recent report, Raizen et al. described
epilepsy in HI/HA patients but EEG and clinical data
as well as the follow-up were too scarce to draw
conclusions about the characteristics of the epi-
lepsy. In light of this paper, the spectrum of epilepsy
in HI/HA appear to be diverse, although the authors
however did describe absences with eye or eyelid
myoclonia in 2 siblings and another case4 (additional
table).In our family, the epilepsy was clearly character-
ized by video-EEG recording which showed in both
sisters photosensitive myoclonic absence seizures
with generalized irregular spike and spike-wave
discharges. Their seizures started at 2 years of
age and were resistant to antiepileptic drugs,
although levetiracetam slightly reduced their
frequency.
Concerning epilepsy, we could observe a distinc-
tive electroclinical phenotype that consists of
photosensitive myoclonic absence seizures. These
seizures recall the myoclonic absence like seizures
occasionally observed in chromosome abnormalities
and in succinic semialdehyde dehydrogenase
(SSADH) deficiency.11—13 They are characterized
by the combination of atypical absence with a long
duration of impairment of consciousness and myo-
clonic jerks involving the proximal muscles of the
limbs particularly the deltoids. Falling or simple
head nodding can occur in 50% of the cases
described, and others seizures types, such as com-
plex partial, tonic or clonic seizures can also be
associated also in 50% of the cases.11—13 As it as been
described in patients with chromosomal abnormal-
ities, this form of myoclonic absence like epilepsy in
HHS patients tends to be refractory to antiepileptic
drugs.11—13
In that condition, carbamazepine or its structural
relative oxcarbazepine should be avoided since this
antiepileptic drugs are known to worsen myoclonic
epilepsy as well as absence seizure. Conversely, a
combination of levetiracetam, valproic acid and/or
zonisamide could proposed with a potential better
benefit in seizure control.
There are several possible mechanisms underly-
ing the epilepsy observed in the HI/HA syndrome. It
could be a consequence of repeated hypoglycemic
events leading to permanent brain injury. It could
also be the consequence of chronic hyperammone-
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epilepsy could directly result from mutations in the
GLUD1 gene leading to an activation of the GDH in
brain.
In our family, hypoglycemia cannot solely explain
the myoclonic epilepsy as the serum and cerebro-
spinal fluid glucose levels were normal in the index
case during the active phase of the epilepsy and in
addition the younger sister and brother were not
known to have suffered from hypoglycemic events.
Moreover, contrary to cerebral abnormalities seen
as a consequence of hypoglycemic events,14,15 ima-
ging findings were normal in all our patients and, in
particular, they do not show any structural abnorm-
alities previously observed in HI/HA patients (left
frontal encephalomalacia, general cerebral atro-
phy, left frontal porencephalic cyst).4 This argues
against the theory of brain injury or hypoglycemic
sequellae.
With regards to the hyperammonemia hypoth-
esis, the hyperammonemia remained asymptomatic
and stable in our patients, as demonstrated by the
absence of acute neurological symptoms and the
absence of mental retardation in the mother. We
also observed normal glutamine level in the CSF with
no abnormal peak of glutamine detected on MRS.
This argues against the theory of brain toxicity
secondary to hyperammonemia. Moreover, overac-
tivity of GDH is supposed to protect the central
nervous system against some effects of hyperam-
monemia by preventing excessive accumulation of
glutamate and glutamine in brain and maintaining a
normal neuronal glutamate pool.2,9
The most plausible explanation rests with over-
activity of GDH which might alter the concentration
of GABA by decreasing brain glutamine and conse-
quently brain GABA. Thus, abnormal concentrations
of glutamate and GABA could constitute one puta-
tive mechanism of epilepsy in HI/HA syndrome, as
shown in myoclonic absence epilepsy secondary to
SSADH deficiency.13 The fact that all our patients
described the same pattern of epilepsy provides a
plausible explanation for this hypothesis. However,
contrary to SSADH deficiency, CSF neurotransmitters
were normal.
Finally, the mechanism of this epilepsy could be
related to a cerebral KATP channel dysfunction which
is also expressed in the brain. Overactivity of GDH
leads to closure of ATP sensitive potassium channels
(KATP) by increasing ATP/ADP ratio, resulting in sus-
tained neuronal depolarization. Recent reports of
an activating mutation in the Kir6.2, subunit of the
KATP channel in DEND syndrome (developmental
delay, epilepsy or muscle weakness, neonatal dia-
betes) also argues for this hypothesis.16 In DEND
syndrome, Kir6.2 mutations cause an increase inwhole resting cell KATP currents by reducing channel
inhibition by ATP. This could induce neuronal hyper-
excitability and seizures.17,18 However, in hyperin-
sulinemic hypoglycemia in which mutations in SUR1
or Kir6.2 genes are inhibiting mutations leading to
close of the channels, epilepsy is rarely described
despite severe hypoglycemia.19
In conclusion, we report one family with a gain of
function mutation in GDH with an original pheno-
type of photosensitive myoclonic absence epilepsy.
In this case report, we give new details about the
electrophysiological pattern associated with this
metabolic disorder and metabolic data that give
new insight into the pathophysiological mechanism
of this epilepsy.Acknowledgment
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